Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ATRA, unsubscribe in one click. Privacy
ATRA reported $12.8M in cash and short-term investments (as of Jun 30, 2026) and used about $3.2M/quarter in operations, an estimated runway of 11.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 84 · High
Accordingly, we have concluded that substantial doubt exists with respect to our ability to continue as a going concern for at least 12 months after the issuance of the accompanying condensed consolidated financial statements.10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ATRA files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| EcoR1 Capital, LLC | Institution (13G, 5%+) | 1,552,000 | 15.46% | 2026-05-07 |
| Adiumentum Capital Fund I LP | Institution (13G, 5%+) | 1,370,081 | 13.65% | 2025-05-14 |
| Panacea Innovation Limited | 5%+ holder (13D) | 1,318,894 | 13.14% | 2026-05-07 |
| Redmile Group, LLC | Institution (13G, 5%+) | 950,994 | 9.47% | 2026-07-22 |
| Adage Capital Management, L.P. | Institution (13G, 5%+) | 700,000 | 6.97% | 2026-03-31 |
| Point72 Asset Management, L.P. | 5%+ holder (13G) | 687,718 | 6.85% | 2026-06-30 |
Share count 10,037,710 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2026-01-10 | EBVALLO | BLA | -12.9% | -57% | -66.8% |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ATRA and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →